


**Amendments to the Claims:**

Please amend Claims 1-12 and 15 as set forth below. Please cancel Claims 13 and 14. Please add new Claim 16. This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (currently amended) Compounds of the general formula I



Formula I

wherein

Y and Z represent independently from each other hydrogen, fluorine or a methyl group, or Y and Z may together form a cyclopropyl ring; in case k represents the integer 1, Y and Z both represent hydrogen;

X represents  $-(CH_2)_m-N(L)-(CH_2)_m-$ ;  $-CH_2-CH(K)-CH_2-$ ;  $-CH_2CH_2-$ ;  $-CH_2OCH_2-$ ;  $-CH_2SCH_2-$ ;  $-CH_2SOCH_2-$ ;  $-CH_2SO_2CH_2-$ ;  $-CO-NL-CO-$ ;  $-CO-NL-CHR^6-$ ;  $-CHR^6-NL-CO-$ ;

W represents a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

V represents a bond;  $-(CH_2)_r-$ ;  $-A-(CH_2)_s-$ ;  $-CH_2-A-(CH_2)_t-$ ;  $-(CH_2)_s-A-$ ;  $-(CH_2)_2-A-(CH_2)_u-$ ;  $-A-(CH_2)_v-B-$ ;  $-CH_2-CH_2-CH_2-A-CH_2-$ ;  $-A-CH_2-CH_2-B-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-B-$ ;  $-CH_2-CH_2-CH_2-A-CH_2-CH_2-$ ;  $-CH_2-CH_2-CH_2-CH_2-A-CH_2-$ ;  $-A-CH_2-CH_2-B-CH_2-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-B-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-CH_2-B-$ ; or  $-CH_2-CH_2-A-CH_2-CH_2-B-$ ;  $-O-CH_2-CH(OCH_3)-CH_2-O-$ ;  $-O-CH_2-CH(CH_3)-CH_2-O-$ ;  $-O-CH_2-CH(CF_3)-CH_2-O-$ ;  $-O-CH_2-C(CH_3)_2-CH_2-O-$ ;  $-O-CH_2-C(CH_3)_2-O-$ ;  $-O-C(CH_3)_2-CH_2-O-$ ;  $-O-CH_2-CH(CH_3)-O-$ ;  $-O-CH(CH_3)-CH_2-O-$ ;  $-O-CH_2-C(CH_2CH_2)-O-$ ;  $-O-C(CH_2CH_2)-CH_2-O-$ ;

A and B independently represent  $-O-$ ;  $-S-$ ;  $-SO-$ ;  $-SO_2-$ ;

U represents aryl; heteroaryl;

T represents  $-CONR^1-$ ;  $-(CH_2)_pOCO-$ ;  $-(CH_2)_pN(R^1)CO-$ ;  $-(CH_2)_pN(R^1)SO_2-$ ; or  $-COO-$ ;

Q represents lower alkylene; lower alkenylene;

M represents aryl- $O(CH_2)_vR^5$ ; heteroaryl- $O(CH_2)_vR^5$ ; aryl- $O(CH_2)_vO(CH_2)_wR^5$ ; heteroaryl- $(CH_2)_vO(CH_2)_wR^5$ ; aryl- $OCH_2CH(R^7)CH_2R^5$ ; heteroaryl- $OCH_2CH(R^7)CH_2R^5$ ;

L represents  $-R^3$ ;  $-COR^3$ ;  $-COOR^3$ ;  $-CONR^2R^3$ ;  $-SO_2R^3$ ;  $-SO_2NR^2R^3$ ;

$-COCH(Aryl)_2$ ;

K represents  $-H$ ;  $-CH_2OR^3$ ;  $-CH_2NR^2R^3$ ;  $-CH_2NR^2COR^3$ ;  $-CH_2NR^2SO_2R^3$ ;  $-CO_2R^3$ ;  $-CH_2OCONR^2R^3$ ;  $-CONR^2R^3$ ;  $-CH_2NR^2CONR^2R^3$ ;  $-CH_2SO_2NR^2R^3$ ;  $-CH_2SR^3$ ;  $-CH_2SOR^3$ ;  $-CH_2SO_2R^3$ ;

$R^1$  represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

$R^2$  and  $R^{2'}$  independently represent hydrogen; lower alkyl; lower alkenyl; cycloalkyl; cycloalkyl - lower alkyl;

$R^3$  represents hydrogen; lower alkyl; lower alkenyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl - lower alkyl; aryl - lower alkyl; heteroaryl - lower alkyl; heterocyclyl - lower alkyl; aryloxy - lower alkyl; heteroaryloxy - lower alkyl, whereby these groups may be unsubstituted or mono-, di- or trisubstituted with hydroxy,  $-\text{OCOR}^2$ ,  $-\text{COOR}^2$ , lower alkoxy, cyano,  $-\text{CONR}^2\text{R}^{2'}$ ,  $-\text{CO-morpholin-4-yl}$ ,  $-\text{CO-((4-loweralkyl)piperazin-1-yl)}$ ,  $-\text{NH(NH)NH}_2$ ,  $-\text{NR}^4\text{R}^{4'}$  or lower alkyl, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is  $\text{sp}^3$ -hybridized;

$R^4$  and  $R^{4'}$  independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl - lower alkyl; hydroxy - lower alkyl;  $-\text{COOR}^2$ ;  $-\text{CONH}_2$ ;

$R^5$  represents  $-\text{OH}$ , lower alkoxy,  $-\text{OCOR}^2$ ,  $-\text{COOR}^2$ ,  $-\text{NR}^2\text{R}^{2'}$ ,  $-\text{OCONR}^2\text{R}^{2'}$ ,  $-\text{NCONR}^2\text{R}^{2'}$ , cyano,  $-\text{CONR}^2\text{R}^{2'}$ ,  $\text{SO}_3\text{H}$ ,  $-\text{SONR}^2\text{R}^{2'}$ ,  $-\text{CO-morpholin-4-yl}$ ,  $-\text{CO-((4-loweralkyl)piperazin-1-yl)}$ ,  $-\text{NH(NH)NH}_2$ ,  $-\text{NR}^4\text{R}^{4'}$ , with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is  $\text{sp}^3$ -hybridized;

$R^6$  represents hydrogen; lower alkyl; lower alkoxy, whereby these groups may be unsubstituted or monosubstituted with hydroxy,  $-\text{CONH}_2$ ,  $-\text{COOH}$ , imidazolyl,  $-\text{NH}_2$ ,  $-\text{CN}$ ,  $-\text{NH(NH)NH}_2$ ;

$R^7$  represents  $-\text{OH}$ ,  $\text{OR}^2$ ;  $\text{OCOR}^2$ ;  $\text{OCOOR}^2$ ; or  $R^6$  and  $R^5$  form together with the carbon atoms to which they are attached a 1,3-dioxolane ring which is substituted in position 2 with  $R^2$  and  $R^{2'}$ ; or  $R^6$  and  $R^5$  form together with the carbon atoms to which they are attached a 1,3-dioxolan-2-one ring;

k is the integer 0 or 1;

m and n represent the integer 0 or 1, with the proviso that in case m represents the integer 1, n is the integer 0; in case n represents the integer 1, m is the integer 0; in case k represents the integer 0, n represents the integer 0; in case X does not represent  $-(CH_2)_m-N(L)-(CH_2)_m-$ , n represents the integer 0;

p is the integer 1, 2, 3 or 4;

r is the integer 1, 2, 3, 4, 5, or 6;

s is the integer 1, 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

v is the integer 1, 2, 3, or 4;

w is the integer 1 or 2;

~~and~~ in any form, including optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as free or pharmaceutically acceptable salts, solvent complexes and morphological forms.

2. (currently amended) Compounds according to claim 1, wherein

Y and Z represent independently from each other hydrogen, fluorine or a methyl group, or Y and Z may together form a cyclopropyl ring;

X represents  $-\text{CH}_2-\text{CH}(\text{K})-\text{CH}_2-$ ;  $-\text{CH}_2\text{CH}_2-$ ;  $-\text{CH}_2\text{OCH}_2-$ ;  $-\text{CH}_2\text{SCH}_2-$ ;  $-\text{CH}_2\text{SOCH}_2-$ ;  
 $-\text{CH}_2\text{SO}_2\text{CH}_2-$ ;  $-\text{CO}-\text{NL}-\text{CHR}^6-$ ;  $-\text{CHR}^6-\text{NL}-\text{CO}-$ ;

W represents a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

V represents a bond;  $-(\text{CH}_2)_r-$ ;  $-\text{A}-(\text{CH}_2)_s-$ ;  $-\text{CH}_2-\text{A}-(\text{CH}_2)_t-$ ;  $-(\text{CH}_2)_s-\text{A}-$ ;  $-(\text{CH}_2)_2-\text{A}-(\text{CH}_2)_u-$ ;  $-\text{A}-(\text{CH}_2)_v-\text{B}-$ ;  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{A}-\text{CH}_2-$ ;  $-\text{A}-\text{CH}_2-\text{CH}_2-\text{B}-\text{CH}_2-$ ;  $-\text{CH}_2-\text{A}-\text{CH}_2-\text{CH}_2-\text{B}-$ ;  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{A}-\text{CH}_2-$ ;  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{A}-\text{CH}_2-$ ;  $-\text{A}-\text{CH}_2-\text{CH}_2-\text{B}-\text{CH}_2-\text{CH}_2-$ ;  $-\text{CH}_2-\text{A}-\text{CH}_2-\text{CH}_2-\text{B}-\text{CH}_2-$ ;  $-\text{CH}_2-\text{A}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{B}-$ ; or  $-\text{CH}_2-\text{CH}_2-\text{A}-\text{CH}_2-\text{CH}_2-\text{B}-$ ;  $-\text{O}-\text{CH}_2-\text{CH}(\text{OCH}_3)-\text{CH}_2-\text{O}-$ ;  
 $-\text{O}-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{O}-$ ;  $-\text{O}-\text{CH}_2-\text{CH}(\text{CF}_3)-\text{CH}_2-\text{O}-$ ;  $-\text{O}-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{O}-$ ;  $-\text{O}-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{O}-$ ;  
 $-\text{O}-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{O}-$ ;  $-\text{O}-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{O}-$ ;  $-\text{O}-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{O}-$ ;  $-\text{O}-\text{CH}_2-\text{C}(\text{CH}_2\text{CH}_2)-\text{O}-$ ;  
 $-\text{O}-\text{C}(\text{CH}_2\text{CH}_2)-\text{CH}_2-\text{O}-$ ;

A and B independently represent  $-\text{O}-$ ;  $-\text{S}-$ ;  $-\text{SO}-$ ;  $-\text{SO}_2-$ ;

U represents aryl; heteroaryl;

T represents  $-\text{CONR}^1-$ ;  $-(\text{CH}_2)_p\text{OCO}-$ ;  $-(\text{CH}_2)_p\text{N}(\text{R}^1)\text{CO}-$ ;  $-(\text{CH}_2)_p\text{N}(\text{R}^1)\text{SO}_2-$ ; or  
 $-\text{COO}-$ ;

Q represents lower alkylene; lower alkenylene;

M represents aryl- $\text{O}(\text{CH}_2)_v\text{R}^8$ ; heteroaryl- $\text{O}(\text{CH}_2)_v\text{R}^8$ ; aryl- $\text{O}(\text{CH}_2)_v\text{O}(\text{CH}_2)_w\text{R}^8$ ; heteroaryl- $(\text{CH}_2)_v\text{O}(\text{CH}_2)_w\text{R}^8$ ; aryl- $\text{OCH}_2\text{CH}(\text{R}^7)\text{CH}_2\text{R}^5$ ; heteroaryl- $\text{OCH}_2\text{CH}(\text{R}^7)\text{CH}_2\text{R}^5$ ;

L represents  $-\text{R}^3$ ;  $-\text{COR}^3$ ;  $-\text{COOR}^3$ ;  $-\text{CONR}^2\text{R}^3$ ;  $-\text{SO}_2\text{R}^3$ ;  $-\text{SO}_2\text{NR}^2\text{R}^3$ ;  
 $-\text{COCH}(\text{Aryl})_2$ ;

K represents  $-H$ ;  $-CH_2OR^3$ ;  $-CH_2NR^2R^3$ ;  $-CH_2NR^2COR^3$ ;  $-CH_2NR^2SO_2R^3$ ;  $-CO_2R^3$ ;  $-CH_2OCONR^2R^3$ ;  $-CONR^2R^3$ ;  $-CH_2NR^2CONR^2R^3$ ;  $-CH_2SO_2NR^2R^3$ ;  $-CH_2SR^3$ ;  $-CH_2SOR^3$ ;  $-CH_2SO_2R^3$ ;

$R^1$  represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

$R^2$  and  $R^{2'}$  independently represent hydrogen; lower alkyl; lower alkenyl; cycloalkyl; cycloalkyl - lower alkyl;

$R^3$  represents hydrogen; lower alkyl; lower alkenyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl - lower alkyl; aryl - lower alkyl; heteroaryl - lower alkyl; heterocyclyl - lower alkyl; aryloxy - lower alkyl; heteroaryloxy - lower alkyl, whereby these groups may be unsubstituted or mono-, di- or trisubstituted with hydroxy,  $-OCOR^2$ ,  $-COOR^2$ , lower alkoxy, cyano,  $-CONR^2R^{2'}$ ,  $-CO-morpholin-4-yl$ ,  $-CO-((4-loweralkyl)piperazin-1-yl)$ ,  $-NH(NH)NH^2$ ,  $-NR^4R^{4'}$  or lower alkyl, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is  $sp^3$ -hybridized;

$R^4$  and  $R^{4'}$  independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl - lower alkyl; hydroxy - lower alkyl;  $-COOR^2$ ;  $-CONH_2$ ;

$R^5$  represents  $-OH$ , lower alkoxy,  $-OCOR^2$ ,  $-COOR^2$ ,  $-NR^2R^{2'}$ ,  $-OCONR^2R^{2'}$ ,  $-NCONR^2R^{2'}$ , cyano,  $-CONR^2R^{2'}$ ,  $SO_3H$ ,  $-SONR^2R^{2'}$ ,  $-CO-morpholin-4-yl$ ,  $-CO-((4-loweralkyl)piperazin-1-yl)$ ,  $-NH(NH)NH_2$ ,  $-NR^4R^{4'}$ , with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is  $sp^3$ -hybridized;

R<sup>6</sup> represents hydrogen; lower alkyl; lower alkoxy, whereby these groups may be unsubstituted or monosubstituted with hydroxy, -CONH<sub>2</sub>, -COOH, imidazolyl, -NH<sub>2</sub>, -CN, -NH(NH)NH<sub>2</sub>;

R<sup>7</sup> represents -OH, OR<sup>2</sup>; OCOR<sup>2</sup>; OCOOR<sup>2</sup>; or R<sup>6</sup> and R<sup>5</sup> form together with the carbon atoms to which they are attached a 1,3-dioxolane ring which is substituted in position 2 with R<sup>2</sup> and R<sup>2'</sup>; or R<sup>6</sup> and R<sup>5</sup> form together with the carbon atoms to which they are attached a 1,3-dioxolan-2-one ring;

R<sup>8</sup> represents lower alkoxy;

p is the integer 1, 2, 3 or 4;

r is the integer 1, 2, 3, 4, 5, or 6;

s is the integer 1, 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

v is the integer 1, 2, 3, or 4;

w is the integer 1 or 2;

and in any form, including optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as free or pharmaceutically acceptable salts, solvent complexes and morphological forms.

3. (currently amended) Compounds according to ~~any one of claims~~ claim 1 ~~to 2~~ wherein



X represents  $-\text{CH}_2\text{CH}_2-$ .

4. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 3 wherein

T represents  $-\text{CONR}^1-$ ;

Q represents methylene;

M represents aryl- $\text{O}(\text{CH}_2)_v\text{R}^8$ ; heteroaryl- $\text{O}(\text{CH}_2)_v\text{R}^8$ ; aryl- $\text{OCH}_2\text{CH}(\text{R}^7)\text{CH}_2\text{R}^5$ ; heteroaryl- $\text{OCH}_2\text{CH}(\text{R}^7)\text{CH}_2\text{R}^5$ .

5. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 4 wherein

$\text{R}^1$  represents cycloalkyl;

$\text{R}^8$  represents lower alkoxy

v represents 3.

6. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 5 wherein

W represents a 1,4-disubstituted phenyl.

7. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 6 wherein

U is a mono-, di-, or trisubstituted phenyl whereby the substituents are halogen; lower alkyl or lower alkoxy.

8. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 7 wherein

U is a mono-, di-, or trisubstituted phenyl whereby the substituents are selected from fluorine and chlorine.

9. (currently amended) Compounds according to ~~anyone of claims~~ claim 1 to 8 wherein

V represents  $-\text{A}-(\text{CH}_2)_5-$ .

10. (currently amended) Compounds according to ~~any one of claims~~ claim 1 to 9 wherein

A represents –O–, and

s represents 3.

11. (currently amended) The compounds according to ~~any one of claims~~ claim 1 –9 selected from the group consisting of

(*rac.*)-(1*R*\*, 5*S*\*)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-methoxypropoxy)-3-methylpyridin-4-ylmethyl]amide and pure enantiomers thereof, in free or pharmaceutically acceptable salt form.

12. (currently amended) A pharmaceutical composition ~~containing~~ comprising at least one five-membered heteroaryl derivative according to ~~any of claims~~ claim 1 to 11 and in combination or association with a pharmaceutically acceptable carrier materials or adjuvants.

13. (cancelled)

14. (cancelled)

15. (currently amended) A method for the treatment or prophylaxis of diseases which are related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other

diseases known to be related to the renin-angiotensin system, comprising the administration to a patient in need of such treatment or prophylaxis a pharmaceutically active amount of a five-membered heteroaryl derivative according to ~~any of claims~~ claim 1. to 11, ~~or composition according to claim 12.~~

16. (new) The method according to claim 15 wherein the five-membered heteroaryl derivative is (*rac.*)-(1*R*\*, 5*S*\*)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-methoxypropoxy)-3-methylpyridin-4-ylmethyl]amide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.